Inogatran

Names

[ Name ]:
Inogatran

[Synonym ]:
N-((1R)-2-Cyclohexyl-1-(((2S)-2-((3-guanidinopropyl)carbamoyl)piperidino)carbonyl)ethyl)glycine
Inogatran [INN]
{[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID
IGN
Inogatran

Biological Activity

[Description]:

Inogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> Thrombin

Research Areas >> Cardiovascular Disease

[In Vivo]

Inogatran (0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis[1]. Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight. Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model[2].

[References]

[1]. Ignasiak DP, et al. Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog. J Thromb Thrombolysis. 1998 Nov;6(3):199-206.

[2]. Chi L, et al. Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. J Thromb Thrombolysis. 2001 Feb;11(1):19-31.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.36g/cm3

[ Molecular Formula ]:
C₂₁H₃₈N₆O₄

[ Molecular Weight ]:
438.56400

[ Exact Mass ]:
438.29500

[ PSA ]:
164.13000

[ LogP ]:
2.73010

[ Index of Refraction ]:
1.632

[ Storage condition ]:
2-8℃